Humira

Novartis stocks drug cabinet with "Big-3" arthritis blockbusters
Novartis stocks drug cabinet with "Big-3" arthritis blockbusters
Yahoo/Reuters
Novartis
rheumatoid arthritis
generics
Sandoz
Amgen
Enbrel
JNJ
Remicade
AbbVie
Humira
Flag link:
Key Humira patent gets struck down for the second time in as many months
Key Humira patent gets struck down for the second time in as many months
Fierce Pharma
Humira
patents
AbbVie
Boehringer Ingelheim
Coherus Biosciences
Flag link:
Lilly’s Olumiant, spurned by FDA, gets nod from NICE
Lilly’s Olumiant, spurned by FDA, gets nod from NICE
Fierce Pharma
FDA
NICE
Europe
Eli Lilly
olumiant
rheumatoid arthritis
Humira
Flag link:
The 9 Best-Selling Prescription Drugs in 2016 (Each One Topped $6 Billion)
The 9 Best-Selling Prescription Drugs in 2016 (Each One Topped $6 Billion)
Motley Fool
prescription data
Sanofi
Lantus
Roche
Herceptin
Avastin
Celgene
Revlimid
JNJ
Merck
Remicade
Biogen
Rituxan
Amgen
Enbrel
Gilead Sciences
Harvoni
AbbVie
Humira
Flag link:
[video]Will AbbVie Outsmart Biosimilars, and Can Clovis Win the PARP Race?
[video]Will AbbVie Outsmart Biosimilars, and Can Clovis Win the PARP Race?
Motley Fool
AbbVie
biosimilars
Humira
Clovis Oncology
Rubraca
Novartis
Regeneron
Eylea
Flag link:
EMA Recommends New HCV, Cancer and MS Drugs for Approval
EMA Recommends New HCV, Cancer and MS Drugs for Approval
RAPS.org
Europe
EMA
hepatitis C
multiple sclerosis
breast cancer
renal cell carcinoma
AbbVie
Maviret
Gilead Sciences
Vosevi
Biogen
Amgen
Samsung Bioepis
biosimilars
Humira
Novartis
Kisqali
EUSA
Fotivda
Flag link:
AbbVie's Eagerly Anticipated Followup to Humira Is Coming: What You Need to Know
AbbVie's Eagerly Anticipated Followup to Humira Is Coming: What You Need to Know
Motley Fool
AbbVie
Humira
Upadacitinib
JAK inhibitors
autoimmune disease
Flag link:
AbbVie Stock Just Hit a 52-Week High: Here's Why It Should Go Even Higher
AbbVie Stock Just Hit a 52-Week High: Here's Why It Should Go Even Higher
Motley Fool
AbbVie
Humira
Flag link:
Key Humira patent goes down via IPR—but biosims makers shouldn't celebrate yet, analysts warn
Key Humira patent goes down via IPR—but biosims makers shouldn't celebrate yet, analysts warn
Fierce Pharma
Humira
patents
AbbVie
biosimilars
Flag link:
AbbVie Reports Humira Sales Growth in 1st Quarter
AbbVie Reports Humira Sales Growth in 1st Quarter
Yahoo/GuruFocus
AbbVie
Humira
earnings
Flag link:
Lilly and Incyte's Loss Is AbbVie and Regeneron's Gain
Lilly and Incyte's Loss Is AbbVie and Regeneron's Gain
Motley Fool
Eli Lilly
Inctye
AbbVie
Regeneron
rheumatoid arthritis
FDA
baricitinib
Humira
Flag link:
3 Big Biotech Stocks With Big-Time Catalysts
3 Big Biotech Stocks With Big-Time Catalysts
Motley Fool
Regeneron
Praluent
Amgen
biosimilars
Amjevita
Humira
ABP-215
Avastin
ABP-980
Herceptin
Celgene
ozanimod
Flag link:
$5B in Humira sales at stake with Amgen EU approval
$5B in Humira sales at stake with Amgen EU approval
BioPharma Dive
Humira
Amgen
Europe
rheumatoid arthritis
Amgevita
biosimiliars
Flag link:
The 19 Best-Selling Prescription Drugs of All-Time
The 19 Best-Selling Prescription Drugs of All-Time
Motley Fool
Lipitor
Humira
Seretide
Remicade
Plavix
Enbrel
Rituxan
Herceptin
Avastin
Nexium
Zyprexa
Flag link:
Pfizer says rheumatoid arthritis drug is comparable to Humira as combination treatment but not alone
Pfizer says rheumatoid arthritis drug is comparable to Humira as combination treatment but not alone
Marketwatch
Pfizer
Xeljanz
AbbVie
Humira
rheumatoid arthritis
Flag link:
Amgen Gets EU Nod for Humira Biosimilar
Amgen Gets EU Nod for Humira Biosimilar
Investopedia
Amgen
Humira
biosimilars
ABP 501
Flag link:
Boehringer Ingelheim's Humira Biosimilar Under Review by EMA, FDA
Boehringer Ingelheim's Humira Biosimilar Under Review by EMA, FDA
Yahoo/GuruFocus
Boehringer Ingelheim
Humira
biosimilars
FDA
EMA
BI 695501
AbbVie
Flag link:
3 Biggest Risks for AbbVie in 2017
3 Biggest Risks for AbbVie in 2017
Motley Fool
AbbVie
Humira
biosimilars
Imbruvica
Viekira Pak
Elagolix
risankizumab
Flag link:
As Humira readies for biosimilar rivals, AbbVie looks to ASH to build oncology momentum
As Humira readies for biosimilar rivals, AbbVie looks to ASH to build oncology momentum
Fierce Pharma
Humira
AbbVie
biosimilars
ASH
Flag link:
AbbVie's Humira a Step Closer to Approval in Europe
AbbVie's Humira a Step Closer to Approval in Europe
Yahoo/GuruFocus
AbbVie
Humira
Europe
Flag link: